Novartis washes its hands of another bispecific at the center of $2.5B Xencor deal

Max Gelman

Senior Editor

A centerpiece of Novartis’ $2.5 billion bispecifics deal with Xencor has been sidelined, the California biotech said in its third quarter earnings report Monday. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis washes its hands of another bispecific at the center of $2.5B Xencor deal

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Decade after $8B deal, Roche offloads InterMune to mysterious specialty pharma

Boehringer Ingelheim touts success in second Phase 3 lung fibrosis trial

Senators ask FDA to dig into 'misleading' Super Bowl ad from Hims

Pliant pauses Phase 2b lung fibrosis study after safety board recommendation, shares plummet

Roivant discontinues lung disease drug; Bio-Thera, Intas make biosimilar deal

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

No­var­tis wash­es its hands of an­oth­er bis­pe­cif­ic at the cen­ter of $2.5B Xen­cor deal

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novartis washes its hands of another bispecific at the center of $2.5B Xencor deal